All In Biotech

Drug Trial Radar · NCT06798012

A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

A Phase 2, Open-label, Proof-of-Concept Study to Investigate the Efficacy, Safety, and Tolerability of TAK-411 in Adult Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (The CASCA Study)

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

May 14, 2025

Primary completion

Dec 2, 2027

Study completion Jun 8, 2028

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jan 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

CIDP is an autoimmune disease. This means that the body's germ fighting (immune) system attacks itself. In CIDP, the immune system attacks the protective covering around the nerves called myelin. Over time, these nerves lose their ability to send signals to the muscles in the body. This leads to muscle weakness and loss of sensation in arms and legs among other symptoms. Participants with CIDP can be treated with a protein called immunoglobulin (or IG). TAK-411 is a special type of immune globulin G (hsIgG) that has been chemically changed. It is made from IG that comes from human plasma. This study will test if TAK-411 can decrease inflammation and improve symptoms of CIDP. The main aim of this study is to check how TAK-411 affects the physical functioning of adults with CIDP when compared with results of the placebo group of a historical trial. Participants may be treated with TAK-411 for up to 1 year (51 weeks) and will be followed up for 3 weeks after last dose. During the study, participants may visit their study clinic up to approximately 21 times.

Conditions

  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Interventions

  • TAK-411Biological

    TAK-411 IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Improvement in Functional Ability at Week 24Time frame: At Week 24

Locations

22 sites in 3 countries. Site status is shown where the registry gives one.

  • University of California San Diego

    La Jolla, California · Recruiting

  • California Pacific Medical Center

    San Francisco, California · Recruiting

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia · Recruiting

  • UF Health Neurology - Jacksonville

    Jacksonville, Florida · Recruiting

  • Visionary Investigators Network

    Miami, Florida · Recruiting

  • Knight Neurology

    Rockledge, Florida · Recruiting

  • University of South Florida

    Tampa, Florida · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • Mayo Clinic Rochester

    Rochester, Minnesota · Recruiting

  • The Curators of the University of Missouri on behalf of University of Missouri Health Care

    Columbia, Missouri · Recruiting

  • The Washington University

    St Louis, Missouri · Recruiting

  • Velocity Clinical Research - Raleigh

    Raleigh, North Carolina · Recruiting

  • Penn Blood Disorders Program - Hospital of The University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • University of Washington

    Seattle, Washington · Recruiting

  • University of Calgary

    Calgary, Alberta, Canada · Recruiting

  • University Health Network

    Toronto, Ontario, Canada · Recruiting

  • Universidad del Rosario

    Bogotá, Colombia · Recruiting

  • Fundacion Oftalmologica de Santander - FOSCAL

    Bucaramanga, Colombia · Recruiting

  • Neuro ClinicaS.A.S

    Medellín, Antioquia, Colombia · Recruiting

  • Hospital Universitario San Ignacio

    Bogotá, D.C., Colombia · Recruiting

  • Fundacion Valle del Lili

    Cali, Valle del Cauca Department, Colombia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.